Avana: Advanced PDE5 Inhibition for Confident Erection Control
Avana
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 36 | $4.17 | $150.00 (0%) | 🛒 Add to cart |
| 60 | $4.07 | $250.00 $244.00 (2%) | 🛒 Add to cart |
| 88 | $3.99
Best per pill | $366.67 $351.00 (4%) | 🛒 Add to cart |
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 36 | $4.92 | $177.00 (0%) | 🛒 Add to cart |
| 60 | $4.82 | $295.00 $289.00 (2%) | 🛒 Add to cart |
| 88 | $4.76
Best per pill | $432.67 $419.00 (3%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 36 | $3.11 | $112.00 (0%) | 🛒 Add to cart |
| 60 | $3.03 | $186.67 $182.00 (2%) | 🛒 Add to cart |
| 88 | $2.99
Best per pill | $273.78 $263.00 (4%) | 🛒 Add to cart |
Similar products
Avana (avanafil) is a next-generation phosphodiesterase type 5 (PDE5) inhibitor engineered for rapid onset and sustained efficacy in the treatment of erectile dysfunction. Its highly selective mechanism targets the cavernosal smooth muscle with precision, facilitating robust nitric oxide-mediated vasodilation while minimizing off-target effects. Clinically validated for reliability and patient satisfaction, Avana represents a refined therapeutic option for men seeking predictable erectile response with favorable tolerability. This agent combines pharmacokinetic advantages with a well-characterized safety profile, making it a cornerstone in modern sexual medicine protocols.
Features
- Active pharmaceutical ingredient: Avanafil 50 mg, 100 mg, or 200 mg
- High selectivity for phosphodiesterase type 5 (PDE5) enzyme
- Rapid onset of action: as early as 15 minutes post-administration
- Extended duration of efficacy: up to 6 hours
- Minimal interaction with PDE6 (retinal) and PDE1 (cardiac) isoforms
- Film-coated tablet formulation for optimized bioavailability
- Storage stability at room temperature (15–30°C)
Benefits
- Enables reliable and firm erections sufficient for sexual intercourse
- Provides rapid therapeutic effect, reducing planning anxiety and spontaneity barriers
- Sustained window of opportunity supports natural sexual pacing and reduces time pressure
- High PDE5 selectivity lowers incidence of visual disturbances and other class-related side effects
- Supports psychological confidence and relationship satisfaction through predictable efficacy
- Flexible dosing allows individualized titration based on response and tolerability
Common use
Avana is indicated for the treatment of erectile dysfunction (ED) in adult males. It is used to facilitate the achievement and maintenance of penile erection sufficient for satisfactory sexual activity. It is not indicated for use in women, children, or adolescents. Clinical use is predicated on the presence of sexual stimulation; the drug does not automatically induce erection. It may be used in patients with underlying conditions such as diabetes, hypertension, or benign prostatic hyperplasia, following appropriate cardiovascular risk assessment.
Dosage and direction
The recommended starting dose is 100 mg taken orally approximately 15–30 minutes prior to anticipated sexual activity. Dosage may be adjusted to 50 mg (if efficacy is sufficient but side effects are problematic) or increased to 200 mg (if insufficient response at 100 mg and tolerability is acceptable). Do not exceed one dose per 24-hour period. Tablets should be swallowed whole with a glass of water; administration with or without food is acceptable, though high-fat meals may delay time to onset. Individual response duration may vary; sexual stimulation is required for drug effect.
Precautions
- Prior to initiation, clinicians should evaluate cardiovascular status; sexual activity poses potential cardiac risk
- Use with caution in patients with anatomical penile deformity, Peyronie’s disease, or susceptibility to priapism
- Avoid use in patients with severe hepatic impairment (Child-Pugh Class C)
- Caution advised in patients with bleeding disorders or active peptic ulceration
- Not recommended in patients with hereditary degenerative retinal disorders
- Transient decreases in blood pressure may occur; monitor in volume-depleted patients or those on antihypertensives
Contraindications
- Concomitant use with organic nitrates or nitric oxide donors in any form
- History of hypersensitivity to avanafil or any excipient in the formulation
- Concurrent use with guanylate cyclase stimulators (e.g., riociguat)
- Patients with severe cardiovascular instability, including recent myocardial infarction, unstable angina, or life-threatening arrhythmia
- History of non-arteritic anterior ischemic optic neuropathy (NAION)
Possible side effects
- Headache (commonly reported, usually mild to moderate)
- Flushing
- Nasal congestion
- Dyspepsia
- Back pain or myalgia
- Dizziness
- Visual disturbances (e.g., color tinge, blurred vision) – less common than with other PDE5 inhibitors
- Priapism (prolonged erection >4 hours; requires emergency intervention)
- Hearing loss or tinnitus (rare)
Drug interaction
- Nitrates (e.g., nitroglycerin, isosorbide mononitrate): profound hypotension – contraindicated
- Alpha-blockers (e.g., tamsulosin, doxazosin): additive hypotensive effects – avoid concurrent use or initiate at lowest dose with monitoring
- Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase avanafil exposure – maximum dose 50 mg in 24 hours
- Moderate CYP3A4 inhibitors (e.g., erythromycin, aprepitant): caution advised
- Antihypertensives: potential additive blood pressure-lowering effect
- Grapefruit juice: may increase plasma concentrations – avoid consumption
Missed dose
Avana is taken on an as-needed basis. There is no scheduled dosing regimen. If a dose is missed or not taken within the intended window, resume with the next anticipated sexual activity. Do not double the dose or take more than one tablet within 24 hours.
Overdose
In case of suspected overdose, standard supportive measures should be employed. Expected effects may include severe hypotension, syncope, prolonged erection, or cardiovascular events. Priapism requires immediate urological intervention to prevent permanent tissue damage. Hemodynamic support and symptomatic treatment are mainstays of management. Dialysis is unlikely to be effective due to high protein binding.
Storage
Store at room temperature (15–30°C) in the original container. Protect from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on packaging.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or changing your treatment plan. Do not disregard or delay seeking medical advice based on content herein. Not all possible uses, interactions, or adverse effects are listed.
Reviews
Clinical studies and post-marketing surveillance indicate high patient satisfaction with Avana, particularly regarding its rapid onset and reduced side effect profile compared to earlier PDE5 inhibitors. Many users report improved spontaneity and reliability, contributing to enhanced sexual confidence and relationship quality. Medical professionals appreciate its favorable pharmacokinetics and selectivity, making it a preferred option for patients who have experienced side effects with other agents. Long-term adherence appears strong, with low discontinuation rates due to adverse events.